Biogen | BIIB - Cash And Equivalent



Biogen reported $2.76B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
ALKERMES USD 521.2M 121.39M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Bayer EUR 4.56B 542M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Merck USD 8.01B 622M Jun/2025
Moderna USD 1.28B 344M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Sanofi 15.36B 7.37B Jun/2025
Sanofi 15.36B 7.92B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Teva Pharmaceutical Industries USD 2.16B 464M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
United Therapeutics USD 1.59B 306.8M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025